This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Suwannaroj, S Articles by McMurray, R W Search for Related Content PubMed PubMed Citation Articles by Suwannaroj, S Articles by McMurray, R W Social Bookmarking                         What's this?

Suppression of renal disease and mortality in the female NZBNZW F1 mouse model of systemic lupus erythematosus (SLE) by chenodeoxycholic acid

Division of Rheumatology, Department of Medicine, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand

A Lagoo

Department of Pathology, University of Mississippi Medical Center, Jackson, Mississippi, USA

R W McMurray

GV (Sonny) Montgomery VAMC and the University of Mississippi Medical Center; Division of Rheumatology and Molecular Immunology, L525 Clinical Sciences Building, University of Mississippi Medical Center, 2500 North State Street, Jackson, MS 39216, USA.

The objective of this study was to examine the effects of ursodeoxycholic (UDCA) and chenodeoxycholic acid (CDCA) on autoimmune disease in the NZBNZW F¹ (B =W) mouse model of systemic lupus erythematosus (SLE).

The development of murine lupus was assessed in female B/W mice given UDCA or CDCA. At 6 week intervals mice were examined for weight change, albuminuria, anti-DNA antibody and total IgG levels. Morbidity and mortality were assessed daily. UDCA-and CDCA-treated mice were examined at 24 weeks of age for serum cytokines, lymphocyte phenotype, and in vitro cytokine production after immunization with DNP-KLH. Liver and kidneys were examined histopathologically.

The administration of UDCA and CDCA was tolerated without side effects. Weight gain in UDCA-or CDCA-treated and control mice was identical through 24 weeks of age. CDCA, but not UDCA, suppressed the development of renal disease. CDCA-treated B/W mice also had improved survival compared to UDCA-treated or control B/W mice. There were no significant effects of CDCA on anti-DNA antibodies, serum total IgG, or other immunologic parameters. CDCA-treated mice had lower serum IFN-g concentrations compared to control and UDCA-treated mice.

The bile acid, CDCA, significantly inhibited the development of renal disease and modestly prolonged lifespan in the female B/W mouse model of SLE. Suppression of glomerulonephritis was associated with lower serum IFNg concentrations. Further investigation is needed to verify potential mechanisms of action, but these findings suggest that bile acids may alter the development or progression of autoimmunity.

Key Words: bile acids • treatment

Lupus, Vol. 10, No. 8, 562-567 (2001)
DOI: 10.1191/096120301701549697


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?